晚期非小细胞肺癌患者的系统治疗选择。
Customizing systemic therapy in patients with advanced non-small cell lung cancer.
机构信息
Dept of Respiratory Medicine, University Hospital Antwerp, Wilrijkstraat 10, 2650 Antwerp, Belgium.
出版信息
Ther Adv Med Oncol. 2011 Jul;3(4):207-18. doi: 10.1177/1758834011409000.
Abstract
Lung cancer is the leading cause of cancer deaths worldwide. Standard chemotherapy has been shown to improve quality of life and has a modest influence on overall survival. This modest improvement in survival is partly due to the choice of chemotherapy regimens that have been based on prognostic factors such as age, performance status and comorbidities of the patient. This underlines the importance of developing a more personalized therapy for patients with non-small cell lung cancer. Such an approach may reduce the variation in how individual patients respond to medications by tailoring therapies to their genetic profile. In this review we focus on several aspects of customized therapy, looking not only at patient characteristics but also to tumor histology and specific tumor biomarkers.
摘要
肺癌是全球癌症死亡的主要原因。标准化疗已被证明能提高生活质量，并对总生存有适度影响。这种生存的适度改善部分归因于化疗方案的选择，这些方案基于患者的年龄、表现状态和合并症等预后因素。这凸显了为非小细胞肺癌患者开发更个性化治疗的重要性。这种方法可以通过根据患者的遗传特征来调整治疗方法，从而减少个体患者对药物反应的差异。在这篇综述中，我们关注了几种定制治疗的方面，不仅着眼于患者的特征，还着眼于肿瘤组织学和特定的肿瘤生物标志物。
相似文献
1
Customizing systemic therapy in patients with advanced non-small cell lung cancer.晚期非小细胞肺癌患者的系统治疗选择。
Ther Adv Med Oncol. 2011 Jul;3(4):207-18. doi: 10.1177/1758834011409000.
2
Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?晚期非小细胞肺癌（NSCLC）：是否所有患者都需要维持治疗？
Curr Treat Options Oncol. 2012 Dec;13(4):478-90. doi: 10.1007/s11864-012-0209-1.
3
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
4
Current treatments for advanced stage non-small cell lung cancer.晚期非小细胞肺癌的当前治疗方法。
Proc Am Thorac Soc. 2009 Apr 15;6(2):233-41. doi: 10.1513/pats.200809-110LC.
5
Identifying Subsequent Therapies in Patients with Advanced Non-Small Cell Lung Cancer and Factors Associated with Overall Survival.晚期非小细胞肺癌患者后续治疗的识别及与总生存期相关的因素
Pharmacotherapy. 2016 Oct;36(10):1065-1074. doi: 10.1002/phar.1826. Epub 2016 Sep 25.
6
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
7
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).培美曲塞联合贝伐单抗在既往接受过治疗的晚期非鳞状非小细胞肺癌（ns-NSCLC）患者中的疗效和安全性。
Tumour Biol. 2015 Apr;36(4):2491-9. doi: 10.1007/s13277-014-2862-4. Epub 2014 Nov 25.
8
Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.APPLE（WJOG11218L）研究的治疗原理和设计：阿特珠单抗联合铂类/培美曲塞加或不加贝伐珠单抗治疗晚期非鳞状非小细胞肺癌的多中心、开放标签、随机 3 期研究。
Clin Lung Cancer. 2020 Sep;21(5):472-476. doi: 10.1016/j.cllc.2020.03.010. Epub 2020 Apr 10.
9
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.多西他赛联合卡铂与紫杉醇联合卡铂方案治疗晚期非小细胞肺癌的随机对照Ⅲ期临床研究
Cancer. 2018 May 1;124(9):1982-1991. doi: 10.1002/cncr.30986. Epub 2018 Feb 16.
10
Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.培美曲塞-铂类双药化疗联合或不联合贝伐珠单抗作为中国未经治疗的晚期非鳞状非小细胞肺癌患者一线治疗的疗效比较。
Clin Ther. 2019 Mar;41(3):518-529. doi: 10.1016/j.clinthera.2019.02.004. Epub 2019 Mar 4.
引用本文的文献
1
Paeonol Suppresses Proliferation and Motility of Non-Small-Cell Lung Cancer Cells by Disrupting STAT3/NF-κB Signaling.丹皮酚通过破坏STAT3/NF-κB信号通路抑制非小细胞肺癌细胞的增殖和运动能力。
Front Pharmacol. 2020 Nov 12;11:572616. doi: 10.3389/fphar.2020.572616. eCollection 2020.
2
In silico identification of thiostrepton as an inhibitor of cancer stem cell growth and an enhancer for chemotherapy in non-small-cell lung cancer.计算机模拟鉴定噻唑烷酮类化合物作为非小细胞肺癌肿瘤干细胞生长抑制剂和化疗增敏剂。
J Cell Mol Med. 2019 Dec;23(12):8184-8195. doi: 10.1111/jcmm.14689. Epub 2019 Oct 22.
3
Detecting Mutations in Patients with Non-small Cell Lung Cancer.检测非小细胞肺癌患者的突变
Balkan J Med Genet. 2018 Oct 29;21(1):13-17. doi: 10.2478/bjmg-2018-0013. eCollection 2018 Jun.
4
Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations.临界温度下的差异链分离：一种低丰度未知 DNA 突变的最小干扰富集方法。
Nucleic Acids Res. 2013 Feb 1;41(3):e50. doi: 10.1093/nar/gks1250. Epub 2012 Dec 20.
5
Epigenetics and the transition from acute to chronic pain.表观遗传学与急性痛向慢性痛的转变。
Pain Med. 2012 Nov;13(11):1474-90. doi: 10.1111/j.1526-4637.2012.01488.x. Epub 2012 Sep 14.
本文引用的文献
1
Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor.化疗或表皮生长因子受体酪氨酸激酶抑制剂治疗老年晚期非小细胞肺癌患者预处理合并症的意义。
Med Oncol. 2012 Mar;29(1):185-92. doi: 10.1007/s12032-010-9764-0. Epub 2010 Dec 7.
2
Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review.合并症对实体瘤化疗应用和结局的影响：系统评价。
J Clin Oncol. 2011 Jan 1;29(1):106-17. doi: 10.1200/JCO.2010.31.3049. Epub 2010 Nov 22.
3
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.间变性淋巴瘤激酶抑制在非小细胞肺癌中的作用。
N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448.
4
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.培美曲塞对比吉非替尼对比厄洛替尼用于既往治疗的非小细胞肺癌患者。
Korean J Intern Med. 2010 Sep;25(3):294-300. doi: 10.3904/kjim.2010.25.3.294. Epub 2010 Aug 31.
5
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
6
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.厄洛替尼作为晚期非小细胞肺癌的维持治疗：一项多中心、随机、安慰剂对照的 3 期研究。
Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.
7
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.合并症对接受铂类双药化疗的晚期非小细胞肺癌患者生存、毒性和健康相关生活质量的影响。
Eur J Cancer. 2010 Aug;46(12):2225-34. doi: 10.1016/j.ejca.2010.04.009. Epub 2010 May 12.
8
Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.老年晚期非小细胞肺癌患者的化疗与生存获益。
J Clin Oncol. 2010 May 1;28(13):2191-7. doi: 10.1200/JCO.2009.25.4052. Epub 2010 Mar 29.
9
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.胸苷酸合成酶而非切除修复交叉互补组 1 肿瘤表达可预测培美曲塞为基础化疗治疗的恶性胸膜间皮瘤患者的结局。
J Clin Oncol. 2010 Mar 20;28(9):1534-9. doi: 10.1200/JCO.2009.25.9275. Epub 2010 Feb 22.
10
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).顺铂-吉西他滨联合贝伐珠单抗或安慰剂一线治疗非鳞状非小细胞肺癌的总生存期：一项随机 III 期试验（AVAiL）的结果。
Ann Oncol. 2010 Sep;21(9):1804-1809. doi: 10.1093/annonc/mdq020. Epub 2010 Feb 11.
Zotero 插件